ACL » Topics » Caution Concerning Forward-Looking Statements (Alcon)

This excerpt taken from the ACL 6-K filed Apr 25, 2006.

Caution Concerning Forward-Looking Statements (Alcon)

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, relating mainly to Amgen’s and our ability to bring new products to market from this collaboration or to bring them to market in a timely manner. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements. These statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward- looking statements. Factors that might cause future results to differ include, but are not limited to, the following: this collaboration may never develop any drugs that reach the market, they may reach the market later than other drugs to treat the same conditions or they may not be as effective or safe as such other drugs; the production processes and costs of any potential drugs have not been developed and there is no guarantee that they can be manufactured cost-effectively; changes in government legislation, regulation or reimbursement may reduce the potential revenues from any drugs developed by the collaboration; and other challenges inherent in new product research, development, manufacturing and marketing may not be able to be overcome. You should read this press release with the understanding that our actual future results may be materially different from what we expect. Except to the extent required under the federal securities laws and the rules and regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward- looking statements, whether to reflect new information or future events or circumstances or otherwise.

 

CONTACT: Amgen

Anne McNickle (805) 447-4587 (media)

Tony Gringeri (805) 447-1060 (investors)

www.amgen.com

 

CONTACT: Alcon

Carol Massey (817) 551-8058 (media)

Doug MacHatton (817) 551-8974 (investors)

www.alconinc.com

 

 

 

 

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki